182 related articles for article (PubMed ID: 35422109)
21. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
22. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: Results from the MYONET registry.
Hum RM; Lilleker JB; Lamb JA; Oldroyd AGS; Wang G; Wedderburn LR; Diederichsen LP; Schmidt J; Danieli MG; Oakley P; Griger Z; Phuong TNT; Kodishala C; Vazquez-Del Mercado M; Andersson H; De Paepe B; De Bleecker JL; Maurer B; McCann L; Pipitone N; McHugh N; New RP; Ollier WE; Krogh NS; Vencovsky J; Lundberg IE; ; Chinoy H
Rheumatology (Oxford); 2023 Sep; ():. PubMed ID: 37698987
[TBL] [Abstract][Full Text] [Related]
24. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
25. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
26. SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report.
Arnon J; Elia A; Nevo Y; Lossos A; Nechushtan H
JTO Clin Res Rep; 2021 Sep; 2(9):100217. PubMed ID: 34590056
[TBL] [Abstract][Full Text] [Related]
27. Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis.
Parkes JE; Rothwell S; Oldroyd A; Chinoy H; Lamb JA;
Arthritis Res Ther; 2018 Jun; 20(1):117. PubMed ID: 29884237
[TBL] [Abstract][Full Text] [Related]
28. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
29. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
30. Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China.
Zhao Y; Su H; Yin X; Hou H; Wang Y; Xu Y; Li X; Zhang N; Sun W; Wei W
Med Clin (Barc); 2023 Jan; 160(1):10-16. PubMed ID: 35842306
[TBL] [Abstract][Full Text] [Related]
31. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract][Full Text] [Related]
32. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
[TBL] [Abstract][Full Text] [Related]
33. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
[TBL] [Abstract][Full Text] [Related]
34. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
He L
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
[TBL] [Abstract][Full Text] [Related]
35. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].
Bodoki L; Budai D; Nagy-Vincze M; Griger Z; Betteridge Z; Dankó K
Orv Hetil; 2015 Sep; 156(36):1451-9. PubMed ID: 26320599
[TBL] [Abstract][Full Text] [Related]
37. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
38. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract][Full Text] [Related]
39. A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody".
Koizumi H; Muro Y; Imai S; Yamashita Y; Ogawa-Momohara M; Takeichi T; Murakami M; Mitsuma T; Akiyama M
J Dermatol; 2023 Jan; 50(1):e39-e40. PubMed ID: 36176040
[No Abstract] [Full Text] [Related]
40. Amyopathic dermatomyositis with TIF1? positivity treated with IVIG.
Jiang SW; Kwock JT; Marano AL
Dermatol Online J; 2023 Apr; 29(2):. PubMed ID: 37220289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]